ANXA2 and prostate cancer: A function-blocking anti-ANX2 antibody or a peptide corresponding to the N-terminal amino acids 1–12 of ANX2 containing the minimal p11 binding site prevents the homing and engraftment of HSCs [4], prostate cancer cells [5], and multiple myeloma cells [6] to the bone marrow in irradiated mice.